L-Carnitine functions to transport long chain fatty acyl CoAs into the
mitochondria for degradation by β-oxidation. Treatment with L-carnitine
can ameliorate metabolic imbalance in many inborn errors of metabolism. In
recent years there has been considerable interest in the therapeutic potential
of L-carnitine and its acetylated derivative acetyl-L-carnitine (ALCAR) for
neuroprotection in a number of disorders including hypoxia-ischemia, traumatic
brain injury, Alzheimer’s disease and in conditions leading to central
or peripheral nervous system injury. There is compelling evidence from
preclinical studies that L-carnitine and ALCAR can improve energy status,
decrease oxidative stress and prevent subsequent cell death in models of adult,
neonatal and pediatric brain injury. ALCAR can provide an acetyl moiety that can
be oxidized for energy, used as a precursor for acetylcholine, or incorporated
into glutamate, glutamine and GABA, or into lipids for myelination and cell
growth. Administration of ALCAR after brain injury in rat pups improved
long-term functional outcomes, including memory. Additional studies are needed
to better explore the potential of L-carnitine and ALCAR for protection of
developing brain as there is an urgent need for therapies that can improve
outcome after neonatal and pediatric brain injury.